American Century Companies
NMRA icon

American Century Companies’s Neumora Therapeutics NMRA Stock Holding History

American Century Companies’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.6K Buy
39,810
+973
+3% +$2.52K ﹤0.01% 2794
2025
Q4 		$69.5K Buy
+38,837
New +$85K ﹤0.01% 2781

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

American Century Companies's NMRA Position: Q1 2026 in Review

American Century Companies increased its Neumora Therapeutics (NMRA) stake by 2.5% in Q1 2026, buying an estimated $2.52K and bringing the position to 39,810 shares worth $77.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2794.

American Century Companies first reported a position in NMRA in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • American Century Companies held 39,810 shares of Neumora Therapeutics worth $77.6K as of Q1 2026.
  • American Century Companies bought 973 Neumora Therapeutics shares in Q1 2026, an estimated $2.52K.
  • Neumora Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2794 holding.
  • American Century Companies first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.